| Burkes, Ronald L |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS) |
|
|
| Recruiting | N/A | 1000 | Canada | Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs) | University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc. | Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation | 12/25 | 12/25 | | |
| Shen, Lin |
NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 3 | 194 | RoW | Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI | Hutchison Medipharma Limited | Advanced Neuroendocrine Carcinoma | 05/25 | 05/25 | | |
FG-M108-04, NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. |
|
|
| Recruiting | 3 | 486 | RoW | M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 01/27 | 04/27 | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
NCT06304974: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 488 | RoW | BL-B01D1, Irinotecan, paclitaxel, docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | 05/26 | 05/26 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 05/26 | 06/27 | | |
NCT05352516: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Active, not recruiting | 3 | 478 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech | Postmenopausal | 04/24 | 08/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 506 | RoW | cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo | Akeso | Gastric and Gastroesophageal Junction Adenocarcinoma | 11/26 | 07/27 | | |
NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety |
|
|
| Recruiting | 3 | 590 | RoW | QL1203, Placebo, mFOLFOX6 regimen | Qilu Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 12/24 | 07/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT05987358: A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma. |
|
|
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets | RemeGen Co., Ltd. | Gastric Cancer | 07/24 | 07/25 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
NCT04705519: Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 100 | RoW | Nab-paclitaxel Combined With Bevacizumab | Peking University, Qilu Pharmaceutical Co., Ltd. | Neuroendocrine Carcinoma | 01/22 | 01/24 | | |
KN026-203, NCT04521179: Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors |
|
|
| Completed | 2 | 102 | RoW | KN026 combination, IO therapy | Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University | HER2-positive Solid Tumors | 01/22 | 05/23 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Recruiting | 2 | 55 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 04/25 | 12/25 | | |
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. |
|
|
| Recruiting | 2 | 40 | RoW | SI-B001, Irinotecan | Sichuan Baili Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinomas | 08/24 | 08/24 | | |
| Recruiting | 2 | 200 | RoW | KN035 | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 06/24 | 12/25 | | |
NCT06222944: Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA |
|
|
| Not yet recruiting | 2 | 90 | RoW | Anlotinib, Anlotinib Hydrochloride Capsule, TQB2450, Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound) | Peking University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 08/25 | 08/26 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT04891198: ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 126 | RoW | Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 08/27 | 04/28 | | |
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 47 | RoW | Utidelone and anlotinib | Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Esophageal Cancer | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 360 | RoW | QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 06/26 | 12/27 | | |
NCT05628857: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor |
|
|
| Recruiting | 2 | 240 | RoW | RC108 | RemeGen Co., Ltd. | Digestive Cancer | 10/24 | 10/25 | | |
NCT04923932: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients |
|
|
| Recruiting | 2 | 75 | RoW | Savolitinib, hmpl-504 | Hutchison Medipharma Limited | Gastric Cancer, Esophagogastric Junction Disorder | 04/25 | 10/25 | | |
|
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT06008054: A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors |
|
|
| Recruiting | 2 | 268 | RoW | SI-B003, BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Colorectal Cancer | 12/25 | 12/25 | | |
| Recruiting | 2 | 300 | RoW | Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132 | Gilead Sciences | Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | 2 | 200 | RoW | Tislelizumab (BGB-A317) | BeiGene | MSI-H/dMMR Solid Tumors | 11/26 | 09/27 | | |
| Completed | 1/2 | 65 | RoW | CS3007 (BLU-285) | CStone Pharmaceuticals, Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors | 04/20 | 04/23 | | |
|
|
NCT03565003: A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China |
|
|
| Recruiting | 1/2 | 120 | RoW | JAB-3068 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors | 07/22 | 09/22 | | |
AK109-201, NCT04982276: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 138 | RoW | AK109, paclitaxel, AK104 | Akeso | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 10/25 | 01/27 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT06157827: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 1/2 | 68 | RoW | LBL-024 for Injection, LBL-024, Etoposide Injection, Etoposide, Cisplatin for Injection, Cisplatin, Carboplatin Injection, Carboplatin | Nanjing Leads Biolabs Co.,Ltd | Advanced Neuroendocrine Carcinoma | 11/26 | 07/27 | | |
ORIN1001-C1, NCT05154201: Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care. |
|
|
| Active, not recruiting | 1/2 | 350 | RoW | ORIN1001 | Orinove, Inc., Fosun Pharma | Effect of Drug | 12/24 | 12/24 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 08/24 | 11/24 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 220 | RoW | Dose Escalation, Dose Expansion1, Dose Expansion2, phase II | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Advanced Malignant Solid Tumors | 05/28 | 12/28 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Not yet recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 03/28 | 06/28 | | |
NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT05170958: A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 396 | RoW | LBL-024 for Injection, LBL-024 | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 12/26 | 12/26 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 08/24 | 08/24 | | |
NCT05964543: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors |
|
|
| Recruiting | 1/2 | 72 | RoW | Q-1802 Injection,Oxaliplatin Injection,Capecitabine, Q-1802,Oxaliplatin Injection,Xeloda | QureBio Ltd. | Gastroesophageal Junction (GEJ) Adenocarcinoma | 08/24 | 08/25 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Recruiting | 1/2 | 167 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 08/24 | 12/25 | | |
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 128 | NA | Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 09/24 | 03/25 | | |
NCT05315167: A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 267 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Advanced Solid Tumor, Advanced Solid Malignancies | 11/24 | 03/25 | | |
NCT04632108: A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 214 | RoW | ASKB589 Injection | Jiangsu Aosaikang Pharmaceutical Co., Ltd., Jiangsu Aosaikang Biomedicine Co. LTD. | Malignant Solid Tumor | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 300 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT05830097: A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 260 | US, RoW | CBP-1019, CBP-1019 for injection | Coherent Biopharma (Hefei) Co., Ltd. | Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal | 06/25 | 09/25 | | |
NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours |
|
|
| Recruiting | 1/2 | 392 | RoW | LM-108, Toripalimab | LaNova Medicines Limited | Advanced Solid Tumor | 07/25 | 10/25 | | |
| Recruiting | 1/2 | 368 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06008925: Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 1/2 | 43 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, Nivolumab Injection, OPDIVO | CNBG-Virogin Biotech (Shanghai) Ltd. | Metastatic Gastric Cancer | 12/25 | 06/26 | | |
NCT05167448: A Study of ES104 in Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 1/2 | 58 | RoW | ES104 | Elpiscience (Suzhou) Biopharma, Ltd. | Metastatic Colorectal Cancer | 05/26 | 07/26 | | |
NCT06015048: A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors. |
|
|
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT04740398: A Study of CBP-1008 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1a/1b | 143 | RoW | CBP-1008 | Coherent Biopharma (Suzhou) Co., Ltd. | Advanced Solid Tumor | 09/23 | 03/24 | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
| Completed | 1 | 42 | RoW | 10 mg/kg Q2W, MSB2311 10 Q2W, 20 mg/kg Q3W, MSB2311 20 Q3W | Suzhou Transcenta Therapeutics Co., Ltd. | Advanced Solid Tumor | 01/22 | 01/22 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT03713905: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 293 | RoW | GLS-010, Recombinant Human Anti-PD-1 Monoclonal Antibody | Guangzhou Gloria Biosciences Co., Ltd. | Advanced Solid Tumors | 02/22 | 02/22 | | |
NCT06239623: ERK Inhibitor JSI-1187 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | JSI-1187 | JS InnoPharm, LLC | Solid Tumor, NSCLC, Melanoma | 09/24 | 12/24 | | |
NCT04973098: Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 13 | RoW | CT0181 Cells, CT0181 humanized anti GPC3 autogenous T Cell injection | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Hepatocellular Carcinoma | 08/22 | 06/23 | | |
NCT04040699: KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor |
|
|
| Completed | 1 | 48 | RoW | KN026 combined with KN046 | Peking University, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2 Positive Solid Tumor | 09/22 | 12/23 | | |
NCT05046847: A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 30 | RoW | TQB3811 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Solid Tumor | 10/22 | 12/22 | | |
| Recruiting | 1 | 206 | RoW | SHR-1701 | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 12/22 | | |
NCT04481607: A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets |
|
|
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT04906473: Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 109 | NA | KY100001 | Kunming Pharmaceuticals, Inc. | Advanced Solid Tumor | 12/22 | 10/23 | | |
| Recruiting | 1 | 104 | RoW | QLS31905 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 12/23 | | |
NCT03603951: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms |
|
|
| Recruiting | 1 | 231 | RoW | SHR2554, EZH2 Inhibitor | Jiangsu HengRui Medicine Co., Ltd., Peking University Cancer Hospital & Institute | Relapsed or Refractory Mature Lymphoid Neoplasms | 02/23 | 08/23 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT05393986: Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors |
|
|
| Recruiting | 1 | 63 | RoW | CT048 Autologous Injection (CT048), CT048 Autologous CAR T-cell Injection | Peking University, CARsgen Therapeutics Co., Ltd. | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/23 | 12/24 | | |
NCT05950815: A Study of PM1015 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | CD73 Antigen, PM1015 injection | Biotheus Inc. | Advanced Solid Tumor | 09/23 | 09/24 | | |
NCT06241898: A First-in-human of Multiplle Doses of BB-1709 in Subjects With Locally Advanced/Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 300 | RoW | BB-1709 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Solid Tumor | 06/26 | 12/26 | | |
NCT05167071: HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study |
|
|
| Not yet recruiting | 1 | 61 | NA | HBM4003, Toripalimab | Harbour BioMed (Guangzhou) Co. Ltd. | Solid Tumors | 10/23 | 06/24 | | |
NCT05262491: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor |
|
|
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Gastrointestinal Tumor | 08/24 | 08/24 | | |
NCT06353152: Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1 | 12 | RoW | Claudin18.2-Targeted Chimeric Antigen Receptor T Cell Injection | Peking University, Gracell Biopharmaceuticals, Inc. | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 11/25 | 11/25 | | |
NCT04121286: A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China |
|
|
| Recruiting | 1 | 24 | RoW | JAB-3312 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors | 12/23 | 12/23 | | |
NCT04606472: A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 159 | RoW | SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Solid Tumor | 08/24 | 08/24 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
NCT06170294: MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 20 | RoW | TCR-MAGE-A4 T-Cells, MAGE-A4-directed T cell receptor-engineered T Cells | Peking University, Shanghai Ming Ju Biotechnology Co., Ltd. | Advanced Solid Tumor | 12/25 | 12/28 | | |
NCT06197178: A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) |
|
|
| Recruiting | 1 | 42 | RoW | LCAR-G08 cells | Peking University, Nanjing Legend Biotech Co. | Advanced Gastrointestinal Tumors | 11/25 | 03/28 | | |
| Not yet recruiting | 1 | 110 | NA | XKH002 Injection, XKH002 | Suzhou Kanova Biopharmaceutical Co., LTD | Advanced or Metastatic Solid Tumors | 12/25 | 04/26 | | |
NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
| Recruiting | 1 | 24 | RoW | UCMYM802 Injection | UTC Therapeutics Inc., Peking University Cancer Hospital & Institute | Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer Female | 03/25 | 04/25 | | |
NCT06240546: First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors. |
|
|
| Recruiting | 1 | 102 | RoW | LPM6690176, LY01024 | Luye Pharma Group Ltd. | Advanced Solid Tumor | 02/26 | 02/27 | | |
| Active, not recruiting | 1 | 204 | Europe, Japan, US, RoW | M1774, Tuvusertib, Niraparib | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Metastatic or Locally Advanced Unresectable Solid Tumors | 01/25 | 01/25 | | |
NCT04856150: A Study of Q-1802 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 66 | RoW | Q-1802 | QureBio Ltd. | Advanced Solid Tumors | 04/24 | 07/24 | | |
| Recruiting | 1 | 30 | RoW | BL-M05D1 | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Locally Advanced or Metastatic Solid Tumors | 05/26 | 05/26 | | |
YMCART9601, NCT05287165: Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms |
|
|
| Recruiting | 1 | 19 | RoW | IM96 CAR-T cells | Beijing Immunochina Medical Science & Technology Co., Ltd. | Advanced Solid Tumors, Digestive System Neoplasms, Pancreatic Cancer Resectable, Colorectal (Colon or Rectal) Cancer | 04/24 | 06/24 | | |
NCT05320874: A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors. |
|
|
| Not yet recruiting | 1 | 232 | RoW | KM257 Bispecific antibody | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor | 06/24 | 11/26 | | |
NCT05650242: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1106 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 177 | RoW | BA1106 | Shandong Boan Biotechnology Co., Ltd | Solid Tumors | 06/24 | 12/24 | | |
M108-Ⅰ, NCT04894825: Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China |
|
|
| Recruiting | 1 | 152 | RoW | M108, Chemotherapy, Chemotherapy. | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Advanced Unresectable Solid Tumors | 07/24 | 12/24 | | |
NCT04280341: JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 50 | RoW | RC48-ADC in combinaton with JS001 | Peking University, RemeGen Co., Ltd. | HER2-Positive Solid Tumors | 12/24 | 12/24 | | |
